UK markets close in 3 hours 55 minutes

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,326.40+1.40 (+0.11%)
As of 12:20PM BST. Market open.
Full screen
Previous close1,325.00
Open1,330.80
Bid1,326.20 x 0
Ask1,326.80 x 0
Day's range1,318.40 - 1,344.20
52-week range1,280.92 - 2,746.59
Volume1,258,199
Avg. volume10,939,171
Market cap53.95B
Beta (5Y monthly)0.26
PE ratio (TTM)11.64
EPS (TTM)1.14
Earnings date02 Nov 2022
Forward dividend & yield0.86 (6.57%)
Ex-dividend date18 Aug 2022
1y target estN/A
  • Reuters

    GSK selects Burberry's Brown as its first female CFO

    (Reuters) -Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip British company and a global pharma major. Brown, who has extensive experience in the health and pharmaceutical industry, will join GSK from luxury fashion brand Burberry, in April and take up the job in May.

  • Sky News

    GSK poaches Burberry CFO to create all-female top team

    GSK, the FTSE-100 pharmaceuticals giant, has poached Burberry Group's finance chief to create a rare all-female executive leadership team in London's blue-chip share index. Sky News has learnt that GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019. The appointment of Ms Brown comes during a period of seismic change for GSK, which demerged its consumer healthcare business - now called Haleon - in a £30bn deal in July.

  • Zacks

    Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

    The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.